

Product Data Sheet

Product Name: Emprumapimod

Cat. No.: GC70927

Chemical Properties

Cas. No. 765914-60-1


Formula $C_{24}H_{29}F_2N_5O_3$ M.Wt 473.52

Solubility DMSO : 100 mg/mL (211.18 mM; Storage 4°C, stored under nitrogen
Need ultrasonic; Hygroscopic DMSO
has a significant impact on the
solubility of product, please use
newly opened DMSO)

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38 α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC₅₀=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Emprumapimod (ARRY-797) inhibits LPS-induced IL-6 production from RPMI-8226 cell with an **IC₅₀** value of 100 pM^[1].

Emprumapimod (ARRY-797) (30 mg/kg; p.o.) inhibits the expression of IL-6 (91%) and TNF- α (95%) in SCID-beige mice, inhibits the phosphorylation of p38 in RPMI-8226 xenografts, inhibits the growth of RPMI-8226 tumour (72%) in multiple myeloma (MM) xenograft models^[1].

Emprumapimod (30 mg/kg; p.o.; twice daily for 4 weeks) prevents left ventricular (LV) dilatation and deterioration of fractional shortening (FS) in *Lmna*^{H222P/H222P} mice^[2].

References:

[1]. Dale Wright, et al. ARRY-797, a Potent and Selective Inhibitor of p38 Map Kinase, Inhibits LPS-Induced IL-6 and In Vivo Growth of RPMI-8226 Human Multiple Myeloma Cells.

[2]. Antoine Muchir, et al. Abnormal p38 α mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene mutation. Hum Mol Genet. 2012 Oct 1;21(19):4325-33.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA